Latest filingSep 02, 2026Most recent Form 4
RXRX
RECURSION PHARMACEUTICALS, INC.
NasdaqHealthcareBiological Products, (No Diagnostic Substances)
Insider activity for last month from 08/04 to 09/04. Counts use processed Form 4 rows. Purchase and sale metrics use codes P and S; totals remain unknown when any matching value is missing. Rows without a usable transaction date cannot be assigned to a rolling period and are excluded.
Total buying$00 buys
Total selling$10.0M1 sells
Net open-market-$10.0M4 insiders
Open-market mix
Buy vs sell distribution by transaction countInsider activity report
Monthly open-market purchase and sale counts Buys Sells
Transaction codes
By Form 4 transaction code in selected period4transactions
- F · Tax withholding · dominant3 · 75%
- S · Open-market sells1 · 25%
Activity by reported role
A joint filing can contribute to multiple roles5transactions
- Chief executive officer · dominant1 · 20%
- Chief financial officer1 · 20%
- CSO1 · 20%
- Director1 · 20%
- PRES1 · 20%
Distinct insiders active
Reporting-owner CIKs by month · peak Aug 2026 (3)Aug 2026Sep 2026
Reported Holdings After
Separated by insider, security, and ownership typeTaylor Ben RClass A Common Stock · Direct
1,076,858Aug 17, 2026
Hallett DavidClass A Common Stock · Direct
1,043,837Aug 17, 2026
Khan NajatClass A Common Stock · Direct
2,095,298Aug 17, 2026
Borgeson BlakeClass A Common Stock · Direct
6,158,287Sep 01, 2026
These are reported post-transaction holdings, not company-wide ownership percentages. Securities, indirect vehicles, and amendments are kept separate.
Filing activity heatmap
Each cell is one day · intensity = transactions · buys green, sells redAug 04 → Sep 04
LessMore
Top insiders
By absolute net value across the selected period- KN-$254.4k
- BB-$100.2k
- HD-$84.2k
- TR-$79.1k
Filing detail checks
Secondary metrics for the selected periodFiling-only signals
Deterministic matches in the selected period
RXRX transaction history
Filters apply within this company and selected period by default| Ticker | Insider | Role | Type | Shares | Value | Code | Signals | 90d return | Filed | Trans date |
|---|---|---|---|---|---|---|---|---|---|---|
| RXRX | Borgeson Blake | DIR | sale10b5-1 | 30.0k | -$10.0M | S | — | 0.0% | 09/02 | 09/01 |
| RXRX | Khan Najat | CEOPRES | withholding | 80.4k | -$25.4M | F | +7.8% | 08/18 | 08/17 | |
| RXRX | Hallett David | CSO | withholding | 26.6k | -$8.42M | F | +7.8% | 08/18 | 08/17 | |
| RXRX | Taylor Ben R | CFO | withholding | 25.0k | -$7.90M | F | +7.8% | 08/18 | 08/17 |
RECURSION PHARMACEUTICALS, INC. Insider Activity FAQ
SEC Form 4 contextWho recently reported transactions at RECURSION PHARMACEUTICALS, INC.?
Borgeson Blake, Khan Najat, Hallett David, Taylor Ben R.
When was the latest reported open-market purchase?
No code-P purchase is available for this period.
When was the latest reported open-market sale?
Borgeson Blake reported a sale on Sep 01, 2026 valued at $10.0M. Read the SEC filing.
What is the recent purchase and sale balance?
Net open-market selling in the selected period was $100,200.00. Sales can occur for many non-investment reasons.
Where can I see the original SEC filing?
Every transaction row and latest-activity fact links to its original SEC filing.
What do these Form 4 transaction codes mean?
P and S generally describe open-market or private purchases and sales. A, D, F, M, X, G, J, and V describe awards, issuer dispositions, tax withholding, exercises, gifts, other transactions, and voluntary early reports; review each filing and its footnotes for context.